Orforglipron is Eli Lilly's small-molecule, non-peptide GLP-1 receptor agonist — the first true oral GLP-1 cleared for obesity, branded as Foundayo. Unlike semaglutide and tirzepatide, orforglipron requires no fatty-acid modification and no peptide-stabilizing matrix to survive the gut. The molecule is primarily hepatically metabolized; the label warns against use in severe hepatic impairment, but mild-to-moderate liver impairment is allowed at the standard dose.
The ACHIEVE Phase 3 program covered type-2 diabetes (ACHIEVE-1, ACHIEVE-2), obesity (ACHIEVE-3, ACHIEVE-4), and adjacent indications. The FDA approved the obesity indication in April 2026. Indirect comparisons against oral semaglutide and oral Wegovy have been mixed: orforglipron leads on HbA1c, oral semaglutide may lead on weight loss. By the April 30 Q1 2026 call, roughly 20,000 patients were on the drug, more than 8,000 prescribers had written it, and Lilly confirmed commercial access at two of the three largest US PBMs effective mid-May. On May 4, an FAERS hepatic-failure case logged April 30 surfaced publicly — Lilly's Global Patient Safety team called the event 'not reasonably related to Foundayo,' and the company released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program.
The small-molecule approach carries pricing and manufacturing implications the peptide GLP-1 economy does not — CDMO capacity stops being the bottleneck, and small-molecule generics will eventually follow a different cost curve. Stories here cover trial readouts, post-launch tracking, and competing oral programs.
An FDA Adverse Event Reporting System (FAERS) entry logged April 30 surfaced publicly May 4, documenting hepatic failure in a 56-year-old male patient on Foundayo (orforglipron). The case was marked for expedited review and could have occurred at or before April 15 — Foundayo only launched April 9. There have been 34 total Foundayo FAERS reports so far, with two considered serious. LLY traded down nearly 3% premarket — hitting roughly $936 — before recovering on Lilly's response. Foundayo's label carries a warning that the medication is 'not recommended for use in patients with severe hepatic impairment' (orforglipron is primarily hepatically metabolized), but mild and moderate liver impairment is allowed at standard dose.
On the April 30 call, Lilly USA executive Ilya Yuffa said roughly 20,000 patients are now on Foundayo (orforglipron) for obesity or overweight and more than 8,000 prescribers have written it. Notably, 80% of patients are new to the GLP-1 class and one-third of prescribers had not previously written an oral GLP-1, suggesting Foundayo is expanding the addressable market rather than purely cannibalizing injectables. Lilly also confirmed commercial access at two of the three largest U.S. pharmacy benefit managers effective mid-May. Active sales-force promotion only began the week of April 23, two weeks after broad supply-channel availability on April 9.
Fierce Pharma's Oral GLP-1 Tracker reported May 1 that Eli Lilly's Foundayo (orforglipron) reached 5,612 prescriptions in the week ending April 24 — its third full commercial week — up roughly 51% from Week 2's 3,707 scripts but still behind the Wegovy pill's comparable third-week run. RBC and other analysts continue to caution that 8–12 weeks of data are needed to read commercial trajectory through pharmacy-fill noise. On the Q1 earnings call, Lilly USA's Ilya Yuffa said roughly 20,000 patients are now on the drug for obesity or overweight, calling the early launch 'encouraging.'
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.
Eli Lilly announced positive topline results from ACHIEVE-4, the longest Phase 3 study of Foundayo (orforglipron) to date in 2,700+ adults with type 2 diabetes across 15 countries. The pre-planned analysis showed a 57% lower risk of all-cause death (HR 0.43, p=0.002), while meeting non-inferiority for the prespecified cardiovascular endpoint (HR 0.84). Lilly plans to submit Foundayo for type 2 diabetes to the FDA by end of Q2.
BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.
The FDA asked Eli Lilly for additional safety data on liver injury linked to Foundayo (orforglipron), plus post-marketing trials to assess cardiovascular event risk and delayed gastric emptying. A lactation study was also required. The letter, signed April 1, was published April 14 — just two weeks after the drug's fast-track approval under the National Priority Voucher program.
UBS analysts forecast 5-6 million Foundayo prescriptions in 2026, projecting roughly $2 billion in launch-year sales. RBC Capital Markets projects peak annual US sales of $36 billion. Eli Lilly pre-stocked $1.5 billion of inventory ahead of the April 6 retail launch.
Detailed comparison of Lilly's Foundayo (orforglipron) and Novo's oral Wegovy. Foundayo offers no food/water restrictions; oral Wegovy has brand familiarity and head start. Wall Street predicts slower initial Foundayo uptake.
New ORION study results show oral semaglutide produced greater weight loss and better tolerability than rival orforglipron (Foundayo). Novo also introduced higher-dose Wegovy with aggressive discounts.
Eli Lilly formally launched Foundayo (orforglipron) eight days after FDA approval, having pre-stocked $1.5 billion worth of the drug. The oral obesity market now features a direct Lilly vs Novo Nordisk competition.
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.
An indirect comparison found oral semaglutide may produce greater weight loss than orforglipron, though head-to-head T2D data showed orforglipron had greater HbA1c reductions vs lower-dose oral semaglutide. Lack of CV outcomes data for orforglipron remains a key limitation.
Eli Lilly launched Foundayo on April 1 at $25/month for insured patients and $149 self-pay. The ATTAIN-1 trial showed 12.4% average body weight loss on the highest dose.
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Analysis covers Novo's competitive positioning including ORION study results comparing oral semaglutide against orforglipron, plus up to 48% price cuts in India.